AEON

AEON Biopharma, Inc. (AEON) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. AEON Biopharma, Inc. is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® for therapeutic indications. The company operates as a single segment and is currently in the pre-revenue stage, pursuing a Section 351(k) biosimilar regulatory pathway following the discontinuation of its Phase 2 clinical trials for migraine in May 2024.

Key Financial Metrics

Note: YTD 2024 net income was driven by a $97.5 million gain from the change in fair value of contingent consideration.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased significantly in Q3 2025 ($2.5M) compared to Q3 2024 ($4.0M) and YTD 2025 ($7.3M) compared to YTD 2024 (reported as negative expense due to gains). This reduction is primarily due to the wind-down of Phase 2 clinical trials for migraine and cervical dystonia, resulting in a $0.6 million gain from settling liabilities with clinical research organizations.
• Non-Operating Items: The company recognized a $75.6 million loss on the issuance of warrants in Q1 2025, offset by an $86.0 million gain from the change in fair value of warrants in the YTD 2025 period. In contrast, YTD 2024 included a $97.5 million gain from contingent consideration.
• Liquidity: Cash balances increased from $13,000 at year-end 2024 to $5.9 million at September 30, 2025, driven by a public offering in January 2025 that raised approximately $18.3 million in net proceeds.
• Capital Structure: A 1-for-72 reverse stock split was effected in February 2025. Outstanding shares increased to approximately 11.6 million as of September 30, 2025, largely due to cashless warrant exercises.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The company expects to have sufficient cash to fund operations into the second quarter of 2026, contingent on the closing of a PIPE financing announced in November 2025.
• Strategic Pivot: The company is pursuing a biosimilar pathway for ABP-450 using BOTOX as a reference product. A Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA is confirmed for November 19, 2025, to review analytical study results.
• Financing Activities:
  • PIPE Financing: Entered into an agreement for a private placement of up to $6 million in gross proceeds, closing in two stages in November 2025.
  • Daewoong Exchange: Entered a binding term sheet to exchange $15 million in convertible notes for approximately 23.1 million shares of common stock, a new $1.5 million note, and warrants.
• Listing Compliance: The company received a notice of non-compliance from NYSE American regarding stockholders' equity requirements. A plan to regain compliance by August 3, 2026, has been accepted.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to complex transactions and segregation of duties.

Investor Verification Checklist

• Capital Runway: Verify the closing status and terms of the November 2025 PIPE financing and the Daewoong convertible note exchange to confirm the projected cash runway into Q2 2026.
• Regulatory Milestones: Monitor the outcome of the FDA BPD Type 2a meeting scheduled for November 19, 2025, which is critical for the biosimilar development strategy.
• Listing Status: Track progress on the plan to regain compliance with NYSE American stockholders' equity requirements to avoid potential delisting.
• Dilution Impact: Assess the dilution impact from the proposed exchange of Daewoong notes (approx. 23.1 million shares) and the PIPE financing on existing shareholders.
• Internal Controls: Review the remediation plan for the disclosed material weaknesses in internal controls over financial reporting.